Croda acquires Solus Biotech and expands Pharma business in Asia
Croda announced that it has acquired Solus Biotech, a global leader in premium, biotechnology-derived materials, from Solus Advanced Materials.
Read moreCroda announced that it has acquired Solus Biotech, a global leader in premium, biotechnology-derived materials, from Solus Advanced Materials.
Read moreInside Therapeutics designs, develops and markets instruments and services for manufacturing RNA-based lipid nanoparticles.
Read moreAM-Biotech Consulting offers CMC expertise.
Read moreOsiva published in The Lancet Infectious Diseases results from the company’s OVX836-003 study under the title, “Immunogenicity, safety and preliminary efficacy evaluation of OVX836, a nucleoprotein-based universal influenza A vaccine candidate: randomised, double-blind placebocontrolled, Phase 2a trial.
Read moreOsivax Announces Vaccination of First Participant in Phase 2a Clinical Trial Evaluating OVX836 Combined with QIVs.
Read moreThis is a unique website which will require a more modern browser to work!
Please upgrade today!